Beijing Strong Biotechnologies, Inc.

bsbe.com.cn

Beijing Strong Biotechnologies, Inc. (BSBE) is one of the leading Chinese biotechnology companies. Since its establishment in June, 1988 by several Ph. D graduates from the Chinese Academy of Sciences, BSBE is now one of the fastest growing companies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT

Willow Biosciences | June 01, 2022

news image

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients is pleased to announce today that is has been engaged by a specialty pharmaceutical company (the "Counterparty") to optimize an enzyme vital to the development of a large volume Active Pharmaceutical Ingredient (API) used in nutraceutical and pharmaceu...

Read More

CELL AND GENE THERAPY, MEDTECH

NKARTA ANNOUNCES UPDATED CLINICAL DATA ON ANTI-CD19 ALLOGENEIC CAR-NK CELL THERAPY NKX019 FOR PATIENTS

Nkarta, Inc. | December 06, 2022

news image

Nkarta, Inc. a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma. Seven of ten patients treated at the higher dose levels in a three-dose regimen showed a complete response including two patients with aggressive large B cell lymphoma one patient with mantle cell lymphoma...

Read More

INDUSTRIAL IMPACT

HARBOUR BIOMED ANNOUNCES APPROVAL FOR PHASE I TRIAL OF B7H4X4-1BB BISPECIFIC ANTIBODY IN AUSTRALIA

Harbour BioMed | February 28, 2022

news image

Harbour BioMed announced that, it has been approved by the Institutional Review Boards to commence phase I trial of its B7H4x4-1BB bispecific antibody in Australia. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of HBM7008 in patients with solid tumors. HBM7008 is generated from our unique and innovative HBICE® platform. It targets Tumor Associated Antigen mediated crosslinking T cell activation t...

Read More

MEDTECH

BIO-ISAC AND NEW YORK METRO INFRAGARD MEMBERSHIP ALLIANCE ANNOUNCE PARTNERSHIP

NY Metro InfraGard | April 28, 2022

news image

The Bioeconomy Information Sharing and Analysis Center (BIO-ISAC) and New York Metro InfraGard Members Alliance® (NYM-IMA) today announced a partnership to address threats unique to the bioeconomy and enable coordination among stakeholders to facilitate a robust and secure industry. BIO-ISAC is a critical resource for cyber threat detection, prevention, protection, response, recovery and resilience in the bioeconomy. It helps spur the development and evaluation of defensive to...

Read More
news image

MEDICAL

WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT

Willow Biosciences | June 01, 2022

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients is pleased to announce today that is has been engaged by a specialty pharmaceutical company (the "Counterparty") to optimize an enzyme vital to the development of a large volume Active Pharmaceutical Ingredient (API) used in nutraceutical and pharmaceu...

Read More
news image

CELL AND GENE THERAPY, MEDTECH

NKARTA ANNOUNCES UPDATED CLINICAL DATA ON ANTI-CD19 ALLOGENEIC CAR-NK CELL THERAPY NKX019 FOR PATIENTS

Nkarta, Inc. | December 06, 2022

Nkarta, Inc. a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma. Seven of ten patients treated at the higher dose levels in a three-dose regimen showed a complete response including two patients with aggressive large B cell lymphoma one patient with mantle cell lymphoma...

Read More
news image

INDUSTRIAL IMPACT

HARBOUR BIOMED ANNOUNCES APPROVAL FOR PHASE I TRIAL OF B7H4X4-1BB BISPECIFIC ANTIBODY IN AUSTRALIA

Harbour BioMed | February 28, 2022

Harbour BioMed announced that, it has been approved by the Institutional Review Boards to commence phase I trial of its B7H4x4-1BB bispecific antibody in Australia. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of HBM7008 in patients with solid tumors. HBM7008 is generated from our unique and innovative HBICE® platform. It targets Tumor Associated Antigen mediated crosslinking T cell activation t...

Read More
news image

MEDTECH

BIO-ISAC AND NEW YORK METRO INFRAGARD MEMBERSHIP ALLIANCE ANNOUNCE PARTNERSHIP

NY Metro InfraGard | April 28, 2022

The Bioeconomy Information Sharing and Analysis Center (BIO-ISAC) and New York Metro InfraGard Members Alliance® (NYM-IMA) today announced a partnership to address threats unique to the bioeconomy and enable coordination among stakeholders to facilitate a robust and secure industry. BIO-ISAC is a critical resource for cyber threat detection, prevention, protection, response, recovery and resilience in the bioeconomy. It helps spur the development and evaluation of defensive to...

Read More

Resources

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Document quality control emerges as a discipline in its own right

Whitepaper

resource image

CELL AND GENE THERAPY

What is Population Genomics?

Video

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Document quality control emerges as a discipline in its own right

Whitepaper

resource image

CELL AND GENE THERAPY

What is Population Genomics?

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us